Alumis vs Aquestive Therapeutics
Aquestive Therapeutics reported revenue of $44 million in fiscal 2025, 1.9 times Alumis' $24 million in fiscal 2025. Alumis had an operating margin of -1886.9%, against -159.5% at Aquestive Therapeutics. Free cash flow was −$370 million at Alumis and −$53 million at Aquestive Therapeutics.
Side by side
| Alumis | Aquestive Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $24M | $44M |
| Revenue growth | — | −22.6% |
| Revenue growth a year, last 5 years | — | −0.6% |
| Gross margin | — | 58.4% |
| Operating margin | −1,886.9% | −159.5% |
| Net margin | −1,011.8% | −188.1% |
| Free cash flow | −$370M | −$53M |
| Free cash flow margin | −1,539.2% | −119.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 200.0% | 23.3% |
| Last close | $5.60 | $3.91 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlumisAquestive Therapeutics
Operating margin
Percent of revenue
AlumisAquestive Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlumisAquestive Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alumis and Aquestive Therapeutics pages.